Cumulative Metformin Use and Hepatocellular Carcinoma Risk After HCV SVR : A Multicentre Cohort Study
Liver International · 2026-08 · 46 (8)
DOI: 10.1111/liv.70798 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Liver International, online erschienen am 24.07.2026. Verfasst von Henar Calvo-Sánchez und 14 weiteren Autor:innen. Beteiligte Einrichtung: Service of Gastroenterology, University Hospital of Guadalajara, Guadalajara, Spain. Hauptthemen laut MEDLINE: Antiviral Agents, Carcinoma, Hepatocellular, Hepatitis C, Chronic, Hypoglycemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Agencia Estatal de Investigación.
Abstract (Originalsprache)
Background
Although sustained virological response (SVR) after hepatitis C virus treatment reduces hepatocellular carcinoma (HCC) incidence, residual risk persists. Metformin has been associated with lower HCC risk, but whether cumulative metformin exposure (CME) lowers post‐SVR risk remains unclear. We evaluated whether CME was associated with lower HCC risk after SVR.
Methods
We analysed a multicentre cohort of 1531 patients who achieved SVR after direct‐acting antiviral therapy (median follow‐up, 75.5 months). Metformin exposure was modelled as a time‐updated cumulative variable in start–stop Cox models to control for immortal‐time bias. Stabilised inverse probability weighting addressed confounding by indication and censoring. The overall model was sex‐stratified and adjusted for FIB‐4, clinically significant portal hypertension (CSPH), type 2 diabetes mellitus (T2DM) and smoking. A prespecified T2DM‐restricted analysis used T2DM‐specific IPTW plus IPCW, sex stratification and CSPH adjustment.
Results
During follow‐up, 50 patients developed HCC. Crude incidence was highest among patients with FIB‐4 > 3.25, CSPH and T2DM without metformin exposure (4.84 cases per 100 person‐years). In the overall weighted model, CME was associated with lower HCC risk (HR, 0.46 per year; 95% CI, 0.27–0.77; p = 0.004). CSPH, T2DM, smoking and FIB‐4 > 3.25 independently increased risk. In the T2DM‐restricted model, each additional year remained associated with lower HCC hazard (HR, 0.49; 95% CI, 0.29–0.84; p = 0.009), whereas CSPH was associated with higher risk (HR, 6.04; 95% CI, 2.12–17.19; p < 0.001).
Conclusion
After SVR, CME was associated with lower HCC risk; this possible duration‐dependent inverse association was clinically interpretable only among metformin‐eligible patients with T2DM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service of Gastroenterology, University Hospital of Guadalajara, Guadalajara, Spain.
- Translational Research Group on Cellular Immunology (GITIC), Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), Guadalajara, Spain.
- Department of Medicine and Medical Specialties, University of Alcalá, Alcalá de Henares, Madrid, Spain.
- Service of Gastroenterology, University Hospital Fundación Alcorcón, Madrid, Spain.
- Service of Internal Medicine, University Hospital of Guadalajara, Guadalajara, Spain.
- Department of Biology and Geology, Physics and Inorganic Chemistry, ESCET, Rey Juan Carlos University, Madrid, Spain.
ORCID-Profile: Henar Calvo-Sánchez, Lorena Jara-Fernández, Raquel Encijo-Heredia, Irene Villarino, Rubén Alvarado, Marta Quiñones-Calvo, María-Luisa Gutiérrez, Joaquín Miquel, Miguel Torralba, Myriam Catalá, José Gómez, Sonia Albertos, Óscar Barquero-Pérez, Conrado Fernández-Rodríguez, Juan-Ramón Larrubia
Förderung
- Instituto de Salud Carlos III
- Agencia Estatal de Investigación
Zitieren
APA
Calvo-Sánchez, H., Jara-Fernández, L., Encijo-Heredia, R., Villarino, I., Alvarado, R., Quiñones-Calvo, M., Gutiérrez, M. L., Miquel, J., Torralba, M., Catalá, M., Gómez, J., Albertos, S., Barquero-Pérez, Ó., Fernández-Rodríguez, C., & Larrubia, J. R. (2026). Cumulative Metformin Use and Hepatocellular Carcinoma Risk After HCV SVR : A Multicentre Cohort Study. Liver International, 46(8). https://doi.org/10.1111/liv.70798
Vancouver
Calvo-Sánchez H, Jara-Fernández L, Encijo-Heredia R, Villarino I, Alvarado R, Quiñones-Calvo M, et al. Cumulative Metformin Use and Hepatocellular Carcinoma Risk After HCV SVR : A Multicentre Cohort Study. Liver International. 2026;46(8). doi:10.1111/liv.70798
BibTeX
@article{CalvoSnchez2026,
author = {Calvo-Sánchez, Henar and Jara-Fernández, Lorena and Encijo-Heredia, Raquel and Villarino, Irene and Alvarado, Rubén and Quiñones-Calvo, Marta and Gutiérrez, María-Luisa and Miquel, Joaquín and Torralba, Miguel and Catalá, Myriam and Gómez, José and Albertos, Sonia and Barquero-Pérez, Óscar and Fernández-Rodríguez, Conrado and Larrubia, Juan-Ramón},
title = {Cumulative Metformin Use and Hepatocellular Carcinoma Risk After HCV SVR : A Multicentre Cohort Study},
journal = {Liver International},
year = {2026},
volume = {46},
number = {8},
doi = {10.1111/liv.70798}
}
EUVIMED